TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01153256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulphate
Description: The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Study: NCT00675545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Carboplatin
Description: Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available.
Study: NCT03232138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients
Study: NCT04610151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
Study: NCT02669108

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/ MRI of the Testis
Description: PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
Study: NCT01653847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus with MMF
Description: Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Tacrolimus with Everolimus.
Description: From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
Study: NCT00512044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia (pudendal block)
Description: local anesthesia as indicated
Study: NCT04015882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: The exercise therapy group will make by physiotherapist supervision.
Study: NCT02444143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus extended release
Study: NCT04777188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy
Description: Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
Study: NCT00512044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia (spinal and general)
Description: general according to guidelines
Study: NCT03922971

Intervention type: OTHER
Group type: OTHER
Intervention: Option 1: National comparison
Description: Ability to view center's rate compared with all others.

Intervention type: OTHER
Group type: OTHER
Intervention: Option 2: National comparison with benchmarking
Description: Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
Study: NCT04697992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin c 20%
Description: one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 5mg/ml
Description: one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
Study: NCT04728464

Intervention type: PROCEDURE
Intervention: Periodontally Accelerated Osteogenic Orthodontics (PAOO)
Description: Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
Study: NCT03899103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: First course Course Rituximab at Randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: First course Course Rituximab at Randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
Study: NCT03656549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + oral folinic acid rescue
Description: 3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
Study: NCT02707159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel / gemcitabine
Description: Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
Study: NCT01171833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 2.0 vol% prefilled in a corrugated circuit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: 6.0 vol% prefilled in a corrugated circuit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: 1.2 vol% prefilled in a corrugated circuit.
Study: NCT02592811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Common bile duct cannulation with a cannulation catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Common bile duct cannulation with a cannulation catheter
Study: NCT02284919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]ISO-1
Description: \[18F\]ISO-1 PET/CT scan
Study: NCT01593111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: Home-based environmental intervention
Study: NCT04213339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercises
Description: Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises
Study: NCT04606433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-038
Description: Administration by intravenous infusion.
Study: NCT04002830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elelyso
Description: Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
Study: NCT01544621

Intervention type: OTHER
Intervention: Smoking cessation
Description: Smoking cessation
Study: NCT00686335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra
Description: Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortancyl
Description: Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
Study: NCT02907554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: the intervention group receives 2.5 mg/kg of cyclosporine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group receives a placebo
Study: NCT03008122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study: NCT03997162

Intervention type: OTHER
Intervention: Best Practice
Description: Complete standard of care enhanced recovery after surgery protocol

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03981536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-101
Description: Administered by intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-101
Description: Administered by intravenous infusion (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-101
Description: Administered by intravenous infusion (IV)
Study: NCT00992160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW597599
Description: GW597599 15mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW597599 15mg tablet
Study: NCT03257995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: 150 μg via Concept1 device
Study: NCT02592811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sphincterotomy
Description: Endoscopic large sphincterotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sphincterotomy
Description: Endoscopic large sphincterotomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Large Balloon Dilatation of Oddi Sphincter
Description: Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stone extraction
Description: After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stone extraction
Description: After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
Study: NCT03046914

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA-B*5801 test
Description: Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
Study: NCT00719433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot therapy (ARMin)
Description: therapy of the affected arm with a robot for eight weeks, three times weekly for one hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
Study: NCT03559426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic Reduction
Description: Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic Maintenance
Description: Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
Study: NCT03754192

Intervention type: RADIATION
Group type: OTHER
Intervention: perfusion Computed Tomography
Description: Will be carried before liver surgery
Study: NCT02145611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: Glibenclamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin
Study: NCT03257995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device
Study: NCT02633111

Intervention type: DEVICE
Intervention: PET/CT
Description: at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
Study: NCT03257995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device
Study: NCT00892268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Undergo acupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy
Description: Receive standard care
Study: NCT03678441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainCheck Cognitive Assessment
Description: Receive BrainCheck cognitive assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BrainCheck Cognitive Assessment
Description: Receive BrainCheck cognitive assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Receive pen and paper cognitive assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Receive pen and paper cognitive assessment
Study: NCT05008042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecobalamin 5 MG
Description: The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator : NaCl 9 mg/ml
Description: Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
Study: NCT03815656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN alone
Description: DBS stimulation of STN alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPi alone
Description: DBS stimulation of GPi alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN + GPi
Description: cooperative DBS stimulation of STN and GPi sites

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation
Description: adaptive DBS stimulation of STN and/or GPi sites
Study: NCT04623502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Glucose
Description: Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Acetate
Description: Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Lactate
Description: Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Glutamine
Description: Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Fructose
Description: Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
Study: NCT05829200

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler (TCD)
Description: All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler (TCD)
Description: All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.